Independent guide
What Is a Section 503A Compounding Pharmacy?
Section 503A describes federal conditions under which qualifying compounded drugs can receive exemptions from certain approval, labeling and manufacturing requirements.
Health information: This article is educational, not medical advice. FDA-approved branded medicines and compounded preparations are different regulatory categories. Treatment choice and prescribing require an appropriate clinician.
What matters
Section 503A is not an FDA approval designation for a pharmacy.
Patient-specific prescription requirements are central to the pathway.
Practical checks
Restrictions apply to compounding drugs that are essentially copies of commercially available products.
State boards of pharmacy also play an important regulatory role.
Sources
- HealthRX pricing
- HealthRX FAQ
- FDA: concerns with unapproved GLP-1 drugs
- FDA: 2026 compounding policy clarification
- FDA Wegovy prescribing information
- FDA Zepbound prescribing information
Provider prices and policies can change. We date-check unstable facts and distinguish provider claims from FDA or prescribing-information sources.